ATE297208T1 - Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit - Google Patents

Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit

Info

Publication number
ATE297208T1
ATE297208T1 AT98945805T AT98945805T ATE297208T1 AT E297208 T1 ATE297208 T1 AT E297208T1 AT 98945805 T AT98945805 T AT 98945805T AT 98945805 T AT98945805 T AT 98945805T AT E297208 T1 ATE297208 T1 AT E297208T1
Authority
AT
Austria
Prior art keywords
parkinson
disease
release tablet
extended
treatment
Prior art date
Application number
AT98945805T
Other languages
English (en)
Inventor
Tzu-Chi Robert Ju
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of ATE297208T1 publication Critical patent/ATE297208T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98945805T 1997-09-30 1998-09-03 Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit ATE297208T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6082797P 1997-09-30 1997-09-30
PCT/US1998/017992 WO1999016442A2 (en) 1997-09-30 1998-09-03 Sustained release tablet formulation to treat parkinson disease

Publications (1)

Publication Number Publication Date
ATE297208T1 true ATE297208T1 (de) 2005-06-15

Family

ID=22031996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98945805T ATE297208T1 (de) 1997-09-30 1998-09-03 Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit

Country Status (22)

Country Link
US (2) US6197339B1 (de)
EP (1) EP1017391B1 (de)
JP (1) JP2001517701A (de)
KR (1) KR100516095B1 (de)
CN (1) CN1195518C (de)
AT (1) ATE297208T1 (de)
AU (1) AU742941B2 (de)
BR (1) BR9812687A (de)
CA (1) CA2301869A1 (de)
DE (1) DE69830503T2 (de)
DK (1) DK1017391T3 (de)
ES (1) ES2242296T3 (de)
FI (1) FI20000720L (de)
HU (1) HUP0004586A2 (de)
NO (1) NO320303B1 (de)
NZ (1) NZ504221A (de)
PL (1) PL191125B1 (de)
PT (1) PT1017391E (de)
RU (1) RU2205007C2 (de)
SI (1) SI1017391T1 (de)
SK (1) SK3612000A3 (de)
WO (1) WO1999016442A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767089B2 (en) 1999-02-05 2003-10-30 Pharmacia & Upjohn Company Process to prepare (5R)-(methylamino)-5,6-dihydro-4H- imidazo(4,5,1-ij)-quinolin-2(1H)-one
PL198797B1 (pl) 1999-03-31 2008-07-31 Janssen Pharmaceutica Nv Zastosowanie wstępnie żelowanej skrobi
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
MXPA04005572A (es) * 2001-12-11 2004-12-06 Univ Virginia Uso de pramipexol para tratamiento de esclerosis lateral amiotrofica.
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
EP1545521A2 (de) * 2002-10-04 2005-06-29 Pharmacia Corporation Zusammensetzungen und verfahren zur behandlung der sexuellen dysfunktion
EP1546120A4 (de) * 2002-10-04 2006-11-22 Pharmacia Corp Pharmazeutische zusammensetzung zur behandlung von parkinson-krankheit
EP1569649A2 (de) * 2002-10-25 2005-09-07 Pharmacia & Upjohn Company LLC Verwendung heterozyklischer amine als neuroprotektiva
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
NZ553587A (en) * 2004-08-13 2010-12-24 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmacutically acceptable salt thereof
EA201001086A1 (ru) * 2004-08-13 2011-10-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
US20080234338A1 (en) * 2005-08-15 2008-09-25 University Of Virginia Patent Foundation Neurorestoration With R(+) Pramipexole
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
CA2641665A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101715443A (zh) 2007-03-14 2010-05-26 诺普神经科学股份有限公司 手性纯化的取代的苯并噻唑二胺的合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
EP2758435A1 (de) 2011-09-23 2014-07-30 Roche Glycart AG Bispezifische anti-egfr-/anti-igf-1r-antikörper
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
AU2021464980A1 (en) * 2021-09-17 2024-05-02 Hinova Pharmaceuticals Inc. Quinoline compound sustained-release tablet and preparation method therefor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
ES2067744T3 (es) * 1989-06-09 1995-04-01 Upjohn Co Aminas heterociclicas con actividad sobre el sistema nervioso central.
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
US5000962A (en) 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
GB9605857D0 (en) 1996-03-20 1996-05-22 Tester Richard F Polysaccharides as chemical release systems
CA2173818A1 (fr) 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
PT1017391E (pt) 2005-09-30
FI20000720A7 (fi) 2000-03-29
FI20000720L (fi) 2000-03-29
RU2205007C2 (ru) 2003-05-27
DE69830503D1 (de) 2005-07-14
HUP0004586A2 (hu) 2001-06-28
KR20010030776A (ko) 2001-04-16
PL191125B1 (pl) 2006-03-31
CN1268890A (zh) 2000-10-04
WO1999016442A3 (en) 1999-06-17
DE69830503T2 (de) 2006-03-16
AU9296498A (en) 1999-04-23
NO20001624L (no) 2000-03-29
NO20001624D0 (no) 2000-03-29
KR100516095B1 (ko) 2005-09-23
NO320303B1 (no) 2005-11-21
DK1017391T3 (da) 2005-08-22
NZ504221A (en) 2004-11-26
EP1017391B1 (de) 2005-06-08
CN1195518C (zh) 2005-04-06
BR9812687A (pt) 2000-08-22
SI1017391T1 (sl) 2005-12-31
US6197339B1 (en) 2001-03-06
CA2301869A1 (en) 1999-04-08
ES2242296T3 (es) 2005-11-01
PL339946A1 (en) 2001-01-15
EP1017391A2 (de) 2000-07-12
WO1999016442A2 (en) 1999-04-08
US20010053386A1 (en) 2001-12-20
HK1030163A1 (en) 2001-04-27
JP2001517701A (ja) 2001-10-09
AU742941B2 (en) 2002-01-17
SK3612000A3 (en) 2000-09-12

Similar Documents

Publication Publication Date Title
DE69830503D1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
IS5198A (is) Ný efnasambönd
ES2091689T3 (es) Aplicacion de la carbamazepina y de la oxcarbazepina en el tratamiento de la enfermedad de parkinson y de los sindromes parkinsonianos.
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
DK0793498T3 (da) Bicykliske heterocykliske forbindelser til behandling af impotens
HUP0004350A2 (hu) Vegyületek női szexuális diszfunkció kezelésére
BR9203277A (pt) Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
IS5082A (is) Pýrróló[3,4-D]pýrimídínon-afleiður og notkun þeirra sem lyfja
NO20013645D0 (no) Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjonen av perifere benzodiazepinreseptorer
AR018925A1 (es) Derivados de triazolo-piridazina como ligandos para receptores de gaba, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento.
BG105714A (en) Use of imidazolo[1,5-a]-pyrido[3,2-e]pyrazinons as medicaments
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
TR199801069T2 (xx) Trisiklik 1,4-dihidro-1,4-diokso-1H-naftalen t�revleri ve bunlar�n terap�tik kullan�m�
MXPA05008490A (es) Combinaciones que contienen imidazopiridinas y su uso en el tratamiento de enfermedades gastrointestinales inflamatorias.
TH52800A (th) ไพราโซโลไตรอะซีนที่ถูกแทนที่ที่เป็นซีเลคทีฟอินเวอร์สอะโกนิสท์สำหรับ gaba-a แอลฟา 5 รีเซพเตอร์ซับไทพ์

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017391

Country of ref document: EP

REN Ceased due to non-payment of the annual fee